Research chemicalResearch chemicalPhenethylaminePsychedelic5-HT2A agonistN-benzyl (NBOH)
25E-NBOH
Also known as 2C-E-NBOH · NBOH-2C-E
25E-NBOH is the N-(2-hydroxybenzyl) derivative of 2C-E, an NBOH-series 5-HT2A agonist psychedelic. Orally inactive and taken sublingually, it shares the narrow safety margin, vasoconstriction and seizure risk of the N-benzyl phenethylamine class.
01 Overview
25E-NBOH combines the 2C-E scaffold with the NBOH 2-hydroxybenzyl modification. It is a rare research chemical with no controlled human study.
Information is anecdotal and analytical. The 2C-E parentage suggests a long, introspective psychedelic character, while the NBOH group imposes the class's potency and cardiovascular/neurological hazards.
02 Mechanism
Potent agonist at serotonin 5-HT2A receptors; the N-2-hydroxybenzyl group confers high 5-HT2A affinity on the 2C-E scaffold.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Threshold | 250–600 µg | Sublingual | Estimated; sparse data. |
| Common | 600–1800 µg | Sublingual | Anecdotal; long duration expected. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Long psychedelic experienceExtended visuals and introspective cognitive alteration consistent with the 2C-E backbone. | 8-12 h | Anecdotal | |
| Stimulation and body loadMuscle tension, tremor and restlessness. | moderate-marked | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| VasoconstrictionCold extremities, hypertension and tachycardia over the long duration. | Severe | Common | Anecdotal | |
| Seizures and anxietyOverdose can cause escalating anxiety, agitation and seizures. | Severe | Uncommon | Anecdotal |
06 Legal status
DK
Scheduled NPS
NBOH substances controlled in Denmark. · as of Jan 2026
United States
Federal Analogue Act
Analogue of controlled phenethylamines. · as of Jan 2026
07 References
N-(2-hydroxybenzyl) phenethylamines as selective 5-HT2A agonistsACS Chemical Neuroscience, 2015
EMCDDA NBOH/NBOMe overviewEMCDDA
08 Discussion0 comments
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.